Erickson L D, Hartmann L C, Su J Q, Nielsen S N, Pfeifel D M, Goldberg R M, Levitt R, Stanhope C R
Mayo Clinic, Rochester, Minnesota 55905.
Gynecol Oncol. 1994 Aug;54(2):196-200. doi: 10.1006/gyno.1994.1192.
A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.
一项关于环磷酰胺、顺铂和醋酸亮丙瑞林用于 III 期或 IV 期卵巢癌减瘤术后的 II 期研究，通过一项涉及 11 家机构的合作组研究对 33 例患者进行了观察。其目的是确定添加促性腺激素释放激素类似物是否会改变晚期卵巢癌患者中环磷酰胺和顺铂的缓解率及毒性特征。29 例患者完成了全部 6 个计划周期。在 19 例行二次剖腹探查术的患者中，12 例有持续性疾病，7 例疾病呈阴性。与历史对照相比，促性腺激素释放激素联合化疗并未改变毒性特征或化疗效果。
